2019年度業績集

原著

  1. Safety and efficacy of cold polypectomy compared to endoscopic mucosal resection and hot biopsy polypectomy.Iwashita H, Takedatsu H, Murao H, Funakoshi S, Kuniki Y, Matsuoka S, Tsukamoto S, Yamaguchi M, Shakado S, Kabemura T, Sakisaka S.Scand J Gastroenterol 54(5):678-683, 2019
  2. IL28B Gene Polymorphism Is Correlated with Changes in Low-density Lipoprotein Cholesterol Levels after Clearance of Hepatitis C Virus Using Direct-acting Antiviral Treatment.Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. J Gastroenterol Hepatol 34(11):2019-2027, 2019
  3. Endoscopic and clinicopathological characteristics of gastrointestinal adult T-cell leukemia/lymphoma.Ishibashi H, Nimura S, Kayashima Y, Takamatsu Y, Iwasaki H, Harada N, Momosaki S, Takedatsu H, Sakisaka S, Takeshita M.J　Gastrointest Onco 10(4):723-733, 2019
  4. Development of a C1q-immobilized(Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.Yoshimura N, Yokoyama Y, Sako M, Aoyama N, Hirai F, Sawada K, Kashiwagi N, Suzuki Y.Cytokine 120:54-61,2019
  5. Measurement of prostaglandin metabolites is useful in diagnosis of small bowel ulcerations.Matsuno Y, Umeno J, Esaki M, Hirakawa Y,Fuyuno Y, Okamoto Y, Hirano A, Yasukawa S, Hirai F, Matsui T, Hosomi S, Watanabe K, Hosoe N, Ogata H, Hisamatsu T,Yanai S, Kochi S, Kurahara K, Yao T, Torisu T, Kitazono T, Matsumoto TWorld J　Gastroenterol 25(14):1753-1763,2019
  6. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenacce: a prospective randomised clinical trial (DIAMOND2)Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T, DIAMOND2 Study GroupJ Gastroenterol 54(10):860-870, 2019
  7. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysisHirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T.Journal of Gastroenterology 55（2）,133-141,2020
  8. Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society.Umeshita K, Inomata Y, Furukawa H, Kasahara M, Kawasaki S, Kobayashi E, Kokudo N, Sakisaka S, Shimada M, Tanaka E.Hepatology Research 49（9）:964-980, 2019
  9. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.Inomata S, Anan A, Yamauchi E, Yamauchi R, Kunimoto H, Takata K, Tanaka T, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S.Internal Medicine 58:2915-2922,2019
  10. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakad S, Sakisaka S, Miuma S, Nakao K, Yoshimura Y, Ssasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T.Cancer Medicine 8:2646-2653, 2019

症例報告

  1. Hepatobiliary and Pancreatic: An intraperitoneal gallstone due to gallbladder perforation.Takata K, Matsumoto K, Hirai F.J Gastroenterol Hepatol. 　2020 ;35(3):362.
  2. A Case of Gastric Adenocarcinoma of Fundic Gland Mucosa Type Arising from Helicobacter pylori-Negative MucosaIshibashi H, Nimura S, Tanabe T, Kayashima Y, Matsumoto K, Yamaguchi M, Imakiire S, Shirotani T, Matsuoka H, Yasuda H, Sakisaka H, Matsuoka S, Kunou N, Abe K, Funakoshi S, Takedatsu H, Hirai F.福岡大学医学紀要 47（1）,87-92,2020

総説

  1. 潰瘍性大腸炎の診断基準　Japanese Diagnostic Criteria of Ulcerative Colitis平井郁仁臨牀消化器内科　 34(7):774-778, 2019
  2. 逆行性回腸造影の手技の実際　　福岡大学筑紫病院式小腸造影平井郁仁、頼岡　誠、八尾恒良 胃と腸 54（9）:1295-1298, 2019
  3. 小腸の非腫瘍性疾患　非特異性多発性小腸潰瘍症／CEAS冬野雄太、梅野淳嗣、平野敦士、保利喜史、藤原美奈子、前畠裕司、小林広幸、河内修司、蔵原晃一、安川重義、平井郁仁、鳥巣剛弘、江﨑幹宏胃と腸 54（4）:485-495, 2019
  4. 小腸の非腫瘍性疾患　セリアック病武田輝之、平井郁仁、高津典孝、岸　昌廣、別府剛志、久部高司、宮岡正喜、八尾建史、金城　健、太田敦子、田邉　寛、原岡誠司、岩下明德、長浜　孝、植木敏晴胃と腸 54（4）:515-525, 2019
  5. Crohn病　病型分類髙津典孝、平井郁仁胃と腸　増刊号 54（5）増刊号:720, 2019
  6. Crohn病　モントリオール分類岸　昌廣、平井郁仁胃と腸　増刊号 54（5）増刊号:722-723, 2019
  7. 下痢をきたす疾患の診療　炎症性腸疾患平井郁仁臨牀と研究 96（11）:6-13, 2019
  8. 炎症性腸疾患の内科治療平井郁仁消化器外科 42（12）:1645-1652, 2019
  9. ベドリズマブの作用機序と臨床成績久能宣昭、平井郁仁IBD　Research 13（4）,217-222(29-34)，2019
  10. 消化器疾患の時代的変遷と最近の話題平井郁仁臨牀と研究 97(3), 103-108, 2020

著書

  1. §6-16　門脈圧亢進症横山圭二、向坂彰太郎1361　専門家による私の治療2019-20年度版：日本医事新報社 2019
  2. 基礎13（Q013 白血球除去療法はなぜIBDに有効なのか？）、基礎19（Q019 CDの感受性遺伝子であるTL1A(TNFSF15)はIBDにどのように関与するか？）、基礎20（Q020 sgp130-FcによるIL-6 trans-signalingの制御はIBDの新たな治療法となり得るか？）、基礎21（Q021 STAT3をターゲットとしたJAK/STATシグナル伝達調節はIBDに関与するか？）、基礎29（Q029 IBDを制御できる腸内細菌は存在するか？）　解説竹田津英稔これだけは読んでおきたい！　消化器医のための重要論文240篇 <炎症性腸疾患編>：シービーアール 2019

福岡大学医学部 消化器内科 All Rights Reserved, 2019